Enjoy complimentary customisation on priority with our Enterprise License!
The rapid plasma reagin test market size is forecast to increase by USD 66.6 million, at a CAGR of 5.87% between 2024 and 2028. The Syphilis Testing Market has experienced significant growth due to the increasing incidence of syphilis worldwide. According to the World Health Organization (WHO), there were an estimated 5.6 million new cases of syphilis in 2016, with the highest burden in the WHO African Region. The adoption of serological tests by blood banks is another driving factor for the market's growth. These tests help in the early detection of syphilis in donated blood, ensuring the safety of the blood supply. Additionally, the rising uptake of Rapid Plasma Reagin (RPR) tests in antenatal clinics (ANCs) is contributing to the market's expansion. RPR is a commonly used serological test for the detection of syphilis antibodies in pregnant women, which is essential for the prevention of congenital syphilis.
For More Highlights About this Report, Request Free Sample
The Clinton Health Access Initiative (CHAI), along with partners like MedAccess and SD Biosensor, plays a crucial role in advancing point-of-care diagnostics. These initiatives focus on enhancing the accessibility and reliability of proteins testing strategies, particularly through RPR testing kits and automated RPR systems. In laboratories and specialty clinics, such innovations aim to improve productivity, quality, and consistency of testing results, while minimizing labor overhead. They are instrumental in diagnosing conditions ranging from cerebrospinal fluid infections to Lyme disease and pneumonia, providing timely interventions and appropriate treatments like antibiotics. Through collaborations with diagnostics laboratories and hospitals, these advancements enhance venereal disease research laboratory capabilities, supporting global health efforts to combat infectious diseases effectively. The focus on improving diagnostic tools underscores a commitment to expanding healthcare access and improving patient outcomes worldwide.
The increasing incidence of syphilis is one of the key drivers supporting the rapid plasma reagin test market growth. Syphilis is a sexually transmitted infection (STI) that is caused by the spirochaete treponema pallidum subspecies pallidum. However, the growing incidence of syphilis is a public health concern because of the potential biologic synergy, which can lead to new infections and can further cause the potential spread of it in the general population, including reproductive-aged women. As syphilis infections are often asymptomatic, this limits the use of direct detection approaches which require lesion materials obtained during the early stages of infection. Therefore, diagnostic laboratories and healthcare centers rely on serologic tests, including non-treponemal screening tests such as RPR tests and treponemal confirmatory tests. Thus, these testing strategies will propel the demand for RPR testing kits and instruments during the forecast period. Hence, the increasing global incidence of syphilis will help drive the growth of the rapid plasma reagin test market during the forecast period.
Significant Market Trends
Automated RPR systems is one of the key rapid plasma reagin test market trends that is contributing to the market growth. Automated RPR systems can completely perform sample processing steps, including dilutions, dispenses, and incubations. They can reduce the amount of labor overhead dedicated to rapid plasma reagin testing, freeing laboratory personnel to increase productivity across laboratory operations. These systems can improve the quality and consistency of testing results as the RPR test procedure and results in interpretation are fully automated. Such factors can help to reduce variation associated with manual testing and result interpretation. Furthermore, test results can be directly uploaded to the laboratory database without the need for manual data entry. Such flexible advantages of automated RPR systems will drive the rapid plasma reagin (RPR) test market growth during the forecast period.
Major Market Challenge
Ensuring quality control for syphilis testing is one of the factors hindering the rapid plasma reagin test market growth. Quality control (QC) is the procedure used by diagnostic centers to ensure that each test run is valid and the results obtained are reliable. QC procedures for syphilis testing are included in developing policies at the national level and ensure that the diagnostic tests, including RPR tests used, are of high quality and can provide accurate results. For instance, diagnostic centers may be allowed to use RPR tests kits and instruments which have achieved a certain international standard. These include the European Union CE-mark, US FDA approval, and WHO prequalification. Diagnostic centers can also use RPR tests kits and instruments which have been at least evaluated by a reputable laboratory on performance characteristics such as sensitivity and specificity against a known standard. Thus, these requirements can pose a challenge to the rapid plasma reagin test market growth during the forecast period.
The market forecasting report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
Abbott Laboratories - The company offers rapid plasma reagin tests such as Impact RPR test, which is for the detection of non-treponemal rapid plasma reagin antibodies in human serum or plasma to assist in the diagnosis of syphilis. The test is read by eye so there is no need for a microscope.
The market research and growth report also includes detailed analyses of the competitive landscape of the market and information about key companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
The rapid plasma reagin test kits segments is estimated to witness significant growth during the forecast period. The RPR test kits segment holds a significant market share in the global RPR test market and is expected to show a similar trend during the forecast period owing to the growing availability of the RPR test kits and the high use of assays. RPR test kits are used to determine reagin antibodies in human serum by a slide test method. Reagins is a group of antibodies produced in humans in response to stimulation by a disease known as syphilis. Treponema pallidum, the agent that causes syphilis, produces some amount of damage to the liver and heart, resulting in the release of some tissue fragments. In response to these fragments, the immunological system in patients produces antibodies against these fragments, including reagins.
Get a glance at the market share of various regions Download the PDF Sample
The rapid plasma reagin test kits segments accounted for USD 89.30 million in 2018 and showed a gradual increase during the forecast period. The RPR test kits are macroscopic non-treponemal flocculation test kits that are used for qualitative and semi-quantitative detection of reagin, an antibody present in serum or plasma and spinal fluid in syphilitic patients. RPR test is a modified form of the venereal disease research laboratory (VDRL) test. It contains carbon particles which help improve the visual reading of the test results. When binding occurs between antigens such as cholesterol, cardiolipin, or lecithin present in the reagent and the reagin antibodies of the sample, the results can be seen macroscopically in the form of black clumps. A negative result does not consist of any visual flocculation.
For more insights on the market share of various regions Download PDF Sample now!
North America is estimated to contribute 55% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period. North America accounts for the largest revenue share of the global Rapid Plasma Reagin (RPR) test market. The US and Canada account for the highest market shares in the region. The presence of many vendors that offer RPR test kits, analyzers, and instruments and reagents in the US is a significant factor that drives the growth of the regional market. Furthermore, the high healthcare spending in the US and Canada and the presence of well-established healthcare infrastructure are also fueling the growth of the regional market to a great extent. The US healthcare sector is one of the leading healthcare sectors globally. For instance, in 2023, healthcare spending per person in the US was around USD 14,000-USD 14,500 and it is expected to reach beyond USD 15,000 in 2024. Owing to these factors, the regional RPR test market is expected to grow during the forecast period.
The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD billion " for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.
You may also interested in below market reports:
1. Syphilis Testing Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Canada, Germany, UK, China - Size and Forecast
2. Rapid Diagnostics Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Canada, Japan, Germany, France, China - Size and Forecast
3. Plasma Cutting Machine Market Analysis APAC, Europe, North America, South America, Middle East and Africa - China, US, Germany, Japan, India - Size and Forecast
The Spirochete bacterium Treponema pallidum is the causative agent of syphilis, a global concern due to its pooled prevalence in sexually transmitted infections. Point-of-care diagnostics play a crucial role in early detection, using advanced technologies such as interferometer types and monoclonal antibody tests like Immunofluorescence Test and Fluorescent Treponemal Antibody Absorption Test (FTA-ABS). Syphilis can have severe consequences if untreated, including neonatal death, bone deformities, and increased risk during pregnancy. Diagnostic methods aim to mitigate risks associated with blood draws, such as excessive bleeding, fainting, and hematoma formation, ensuring patient safety while diagnosing conditions like malaria, systemic lupus erythematosus, tuberculosis, and other autoimmune disorders. By leveraging innovative tests and rapid diagnostic tools, healthcare providers can improve outcomes for patients, particularly in managing syphilis and related health complications globally.
Market Scope |
|
Report Coverage |
Details |
Page number |
140 |
Base year |
2023 |
Historic period |
2018-2022 |
Forecast period |
2024-2028 |
Growth momentum & CAGR |
Accelerate at a CAGR of 5.87% |
Market growth 2024-2028 |
USD 66.6 million |
Market structure |
Fragmented |
YoY growth 2023-2024(%) |
5.0 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 55% |
Key countries |
US, France, China, Germany, and Canada |
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Key companies profiled |
Abbott Laboratories, Anamol Laboratories Pvt. Ltd., ARKRAY Inc., Arlington Scientific Inc., Atlas Medical GmbH, Becton Dickinson and Co., Bio Rad Laboratories Inc., Cardinal Health Inc., F. Hoffmann La Roche Ltd., Innovatek Medical Inc., Lorne Laboratories Ltd., Mediclone Biotech, Newmarket Biomedical Ltd., Novacyt SA, Sclavo Diagnostics International S.r.l., Sekisui Chemical Co. Ltd., and Thermo Fisher Scientific Inc. |
Market dynamics |
Parent market analysis, Market forecasting growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period |
Customization purview |
If our market report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Test
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Opportunity/Restraints
10 Competitive Landscape
11 Competitive Analysis
12 Appendix
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.